Skip to main content

Table 3 Resource utilization for Medicare-eligible stage IV ER + breast cancer patients who did not receive HER2 targeted agents and matched comparison patients

From: Survival, healthcare resource use and costs among stage IV ER + breast cancer patients not receiving HER2 targeted therapy: a retrospective analysis of linked SEER-Medicare data

Characteristic Study cohort Comparison cohort P-value*
N 325 325  
Percent hospitalized 83.1% 47.4% < 0.001
  Hospital admissions (PPPM)    
     Mean ± SD 0.2 ± 0.3 0.1 ± 0.1 < 0.001
     Median 0.1 0.0  
  Hospital days (PPPM)    
     Mean ± SD 2.1 ± 3.2 0.4 ± 1.0 < 0.001
     Median 0.7 0.0  
Outpatient    
  Office/clinic visits    
  Percent with outpatient office/clinic visits 90.2% 84.9% 0.057
  Outpatient office/clinic visits (PPPM)    
     Mean ± SD 0.9 ± 0.9 0.4 ± 0.6 < 0.001
     Median 0.8 0.2  
  Physician/provider claims    
  Percent with physician/provider claims 100.0% 98.2% 0.031
  Physician/provider visits (PPPM)    
     Mean ± SD 4.5 ± 3.2 1.8 ± 1.6 < 0.001
     Median 3.5 1.4  
Percent receiving prescription drugs** 58.5% 60.0% 0.750
Percent receiving SNF care 33.2% 17.8% < 0.001
Percent receiving home health care 47.4% 21.2% < 0.001
Percent receiving hospice care 34.2% 7.7% < 0.001
Percent with DME claims 60.0% 45.5% < 0.001
  1. *Proportions were compared using the Fisher's exact test while continuous measures were compared using the nonparametric Wilcoxon test.
  2. **Covered by Part D.
  3. DME: Durable Medical Equipment; PPPM: per-patient-per-month; SNF: Skilled Nursing Facility.